

Marco Volante

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7525030/publications.pdf>

Version: 2024-02-01

205
papers

10,740
citations

22153

59
h-index

39675

94
g-index

208
all docs

208
docs citations

208
times ranked

10108
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities. <i>ESMO Open</i> , 2022, 7, 100308.	4.5	5
2	Tumoral Neuroligin 1 Promotes Cancerâ€“Nerve Interactions and Synergizes with the Glial Cell Line-Derived Neurotrophic Factor. <i>Cells</i> , 2022, 11, 280.	4.1	6
3	Prognostic significance of laterality in lung neuroendocrine tumors. <i>Endocrine</i> , 2022, 76, 733-746.	2.3	8
4	Development and internal validation of a predictive model for the estimation of pheochromocytoma recurrence risk after radical surgery. <i>European Journal of Endocrinology</i> , 2022, 186, 399-406.	3.7	5
5	Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. <i>Endocrine Pathology</i> , 2022, 33, 155-196.	9.0	87
6	Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, , 1.	2.8	1
7	<scp>MicroRNA</scp> profiling predicts positive nodal status in papillary thyroid carcinoma in the preoperative setting. <i>Cancer Cytopathology</i> , 2022, , .	2.4	1
8	Clinical-Pathological Evaluation and Prognostic Analysis of 228 Merkel Cell Carcinomas Focusing on Tumor-Infiltrating Lymphocytes, MCPYV Infection and ALK Expression. <i>Endocrine Pathology</i> , 2022, 33, 289-303.	9.0	2
9	Molecular Subtypes of Extra-pulmonary Neuroendocrine Carcinomas Identified by the Expression of Neuroendocrine Lineage-Specific Transcription Factors. <i>Endocrine Pathology</i> , 2022, 33, 388-399.	9.0	7
10	From SGAP-Model to SGAP-Score: A Simplified Predictive Tool for Post-Surgical Recurrence of Pheochromocytoma. <i>Biomedicines</i> , 2022, 10, 1310.	3.2	3
11	Proposal of a Panel of Genes Identified by miRNA Profiling as Candidate Prognostic Biomarkers in Lung Carcinoids. <i>Neuroendocrinology</i> , 2021, 111, 115-122.	2.5	4
12	Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe. <i>Journal of Clinical Pathology</i> , 2021, 74, 391-395.	2.0	17
13	Malignant struma ovarii: next-generation sequencing of six cases revealed Nras, Braf, and Jak3 mutations. <i>Endocrine</i> , 2021, 71, 216-224.	2.3	12
14	Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2021, 124, 281-289.	6.4	22
15	Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. <i>Human Pathology</i> , 2021, 110, 50-61.	2.0	18
16	A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Nonâ€“small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design. <i>Clinical Lung Cancer</i> , 2021, 22, e63-e66.	2.6	22
17	Risk factors for pancreas and lung neuroendocrine neoplasms: a caseâ€“control study. <i>Endocrine</i> , 2021, 71, 233-241.	2.3	9
18	Outcome and diagnostic reproducibility of the thyroid cytology â€œindeterminate categoriesâ€“SIAPEC/SIE 2014 in a consecutive series of 302 cases. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 803-809.	3.3	7

#	ARTICLE	IF	CITATIONS
19	Primary lung adenocarcinoma in three adolescent patients affected by bone sarcomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 1125-1134.	2.8	1
20	Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. <i>Endocrine Pathology</i> , 2021, 32, 192-210.	9.0	41
21	Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?. <i>Endocrine Pathology</i> , 2021, 32, 63-76.	9.0	55
22	Monoclonal/polyclonal PAX-8, PTH and GATA3 immunohistochemistry in parathyroid lesions. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1997-2008.	3.3	10
23	Neuroendocrine neoplasms of the appendix, colon and rectum. <i>Pathologica</i> , 2021, 113, 19-27.	3.4	36
24	Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocrine Tumors: What Do Pathologists Need to Know?. <i>Endocrine Pathology</i> , 2021, 32, 154-168.	9.0	25
25	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021, 146, 145-154.	2.8	8
26	Diagnostic Value of Conventional PET Parameters and Radiomic Features Extracted from 18F-FDG-PET/CT for Histologic Subtype Classification and Characterization of Lung Neuroendocrine Neoplasms. <i>Biomedicines</i> , 2021, 9, 281.	3.2	10
27	Î²B1± targeting promotes oxidative stress-dependent cell death. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 136.	8.6	8
28	Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2021, 13, 2564.	3.7	16
29	Differential Expression Profiles of Cell-to-Matrix-Related Molecules in Adrenal Cortical Tumors: Diagnostic and Prognostic Implications. <i>Journal of Personalized Medicine</i> , 2021, 11, 378.	2.5	3
30	Adrenal Rests in the Uro-genital Tract of an Adult Population. <i>Endocrine Pathology</i> , 2021, 32, 375-384.	9.0	9
31	Metabolic impairment of non-small cell lung cancers by mitochondrial HSPD1 targeting. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 248.	8.6	18
32	Reply to: Spread Through Air Spaces (STAS). <i>American Journal of Surgical Pathology</i> , 2021, 45, 1439-1440.	3.7	0
33	Outcome of patients with intrathyroidal thymic carcinoma: a pooled analysis. <i>Endocrine-Related Cancer</i> , 2021, 28, 593-604.	3.1	8
34	NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. <i>Cancers</i> , 2021, 13, 4543.	3.7	14
35	Thoracic (Lung/Thymus) Neuroendocrine Neoplasms. , 2021, , 151-206.		2
36	Gross Specimen Handling Procedures Do Not Impact the Occurrence of Spread Through Air Spaces (STAS) in Lung Cancer. <i>American Journal of Surgical Pathology</i> , 2021, 45, 215-222.	3.7	14

#	ARTICLE	IF	CITATIONS
37	Small-Cell Carcinoma of the Lung: What We Learned about It?. <i>Acta Cytologica</i> , 2021, , 1-12.	1.3	3
38	Role of Immunocytochemistry in the Cytological Diagnosis of Pulmonary Tumors. <i>Acta Cytologica</i> , 2020, 64, 16-29.	1.3	22
39	Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy. <i>Hypertension Research</i> , 2020, 43, 500-510.	2.7	26
40	Treatment With 90Y/177Lu-DOTATOC in Patients With Metastatic Adrenocortical Carcinoma Expressing Somatostatin Receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1-e5.	3.6	22
41	Multiple Assays to Determine Methylguanine-Methyltransferase Status in Lung Carcinoids and Correlation with Clinical and Pathological Features. <i>Neuroendocrinology</i> , 2020, 110, 1-9.	2.5	2
42	The Oncocytic Variant of Poorly Differentiated Thyroid Carcinoma Shows a Specific Immune-Related Gene Expression Profile. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4577-e4592.	3.6	8
43	Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation. <i>European Radiology</i> , 2020, 30, 6958-6964.	4.5	10
44	Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas. <i>Vaccines</i> , 2020, 8, 166.	4.4	1
45	Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2642-2653.	3.6	18
46	The IGF2 methylation score for adrenocortical cancer: an ENSAT validation study. <i>Endocrine-Related Cancer</i> , 2020, 27, 541-550.	3.1	3
47	RNA Sequencing Analysis in Primary Mediastinal B Cell Lymphoma: Identification of Different Gene Expression Related to Chemoresistance. <i>Blood</i> , 2020, 136, 1-1.	1.4	0
48	Interleukin-2 Receptor Alpha Chain, Also Called CD25, Is a Potential Target in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 11-12.	1.4	0
49	Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. <i>Nature Communications</i> , 2019, 10, 3407.	12.8	132
50	ACTH-producing tumorlets and carcinoids of the lung: clinico-pathologic study of 63 cases and review of the literature. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 587-597.	2.8	22
51	PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. <i>Modern Pathology</i> , 2019, 32, 1734-1743.	5.5	38
52	The Prognostic Role of CD8+ T Lymphocytes in Childhood Adrenocortical Carcinomas Compared to Ki-67, PD-1, PD-L1, and the Weiss Score. <i>Cancers</i> , 2019, 11, 1730.	3.7	25
53	Malignant peritoneal mesothelioma in a boar who lived in Calabria (Italy): Wild animal as sentinel system of human health. <i>Science of the Total Environment</i> , 2019, 683, 267-274.	8.0	6
54	Spread through air spaces (STAS) is a predictor of poor outcome in atypical carcinoids of the lung. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 325-334.	2.8	18

#	ARTICLE	IF	CITATIONS
55	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1651-1661.	1.1	73
56	Transformation of Prostate Adenocarcinoma Into Small-Cell Neuroendocrine Cancer Under Androgen Deprivation Therapy: Much Is Achieved But More Information Is Needed. <i>Journal of Clinical Oncology</i> , 2019, 37, 350-351.	1.6	25
57	Recent advances in the molecular landscape of lung neuroendocrine tumors. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 281-297.	3.1	38
58	Evaluation of different quantification modes for a simple and reliable determination of Pb, Zn and Cd in soil suspensions by total reflection X-ray fluorescence spectrometry. <i>Journal of Analytical Atomic Spectrometry</i> , 2019, 34, 930-939.	3.0	27
59	Increased production of 27-hydroxycholesterol in human colorectal cancer advanced stage: Possible contribution to cancer cell survival and infiltration. <i>Free Radical Biology and Medicine</i> , 2019, 136, 35-44.	2.9	28
60	Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3 β signaling and inhibition of cellular prostatic acid phosphatase. <i>Cancer Letters</i> , 2019, 449, 252-262.	7.2	19
61	Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. <i>European Journal of Endocrinology</i> , 2019, 180, 387-396.	3.7	38
62	Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. <i>European Journal of Endocrinology</i> , 2019, 181, 681-689.	3.7	30
63	Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms. <i>Endocrine Pathology</i> , 2018, 29, 150-168.	9.0	89
64	High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs. <i>Human Pathology</i> , 2018, 72, 144-152.	2.0	32
65	Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 567-577.	2.8	64
66	Polyol Pathway Links Glucose Metabolism to the Aggressiveness of Cancer Cells. <i>Cancer Research</i> , 2018, 78, 1604-1618.	0.9	83
67	Prognostic Factors: Grading (Ki-67 Index). , 2018, , 107-117.		0
68	Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2018, 143, 199-211.	5.1	21
69	Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms. <i>Endocrine Pathology</i> , 2018, 29, 137-149.	9.0	45
70	Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. <i>Endocrine-Related Cancer</i> , 2018, 25, 583-593.	3.1	77
71	Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas. <i>Modern Pathology</i> , 2018, 31, 1257-1269.	5.5	17
72	Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma. <i>Oncotarget</i> , 2018, 9, 22785-22801.	1.8	4

#	ARTICLE	IF	CITATIONS
73	Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. <i>Cell Metabolism</i> , 2018, 28, 848-865.e6.	16.2	184
74	CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. <i>PLoS ONE</i> , 2018, 13, e0196931.	2.5	10
75	Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review. <i>BMC Cancer</i> , 2018, 18, 311.	2.6	1
76	High miR-100 expression is associated with aggressive features and modulates TORC1 complex activation in lung carcinoids. <i>Oncotarget</i> , 2018, 9, 27535-27546.	1.8	5
77	Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma. <i>Endocrine Pathology</i> , 2017, 28, 95-102.	9.0	15
78	Images in Endocrine Pathology: Unique Composite Adrenal Adenomatoid Tumor, Ganglioneuroma, Myelolipoma, and Cortical Nodular Hyperplasia. <i>Endocrine Pathology</i> , 2017, 28, 276-279.	9.0	3
79	Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1358-1365.	3.6	108
80	Mechanical phenotyping of cells and extracellular matrix as grade and stage markers of lung tumor tissues. <i>Acta Biomaterialia</i> , 2017, 57, 334-341.	8.3	30
81	Distinctive pathological and clinical features of lung carcinoids with high proliferation index. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 713-720.	2.8	64
82	Analysis of histological and immunohistochemical patterns of benign and malignant adrenocortical tumors by computerized morphometry. <i>Pathology Research and Practice</i> , 2017, 213, 815-823.	2.3	5
83	Thymidylate synthase is functionally associated with ZEB1 and contributes to the epithelial-mesenchymal transition of cancer cells. <i>Journal of Pathology</i> , 2017, 242, 221-233.	4.5	30
84	Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma. <i>Human Pathology</i> , 2017, 62, 1-7.	2.0	69
85	Mitochondrial DNA common deletion in post-fine needle aspiration infarcted oncocytic thyroid tumors. <i>Human Pathology</i> , 2017, 69, 23-30.	2.0	4
86	Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1654-1663.	1.1	81
87	Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2017, 177, 361-367.	3.7	25
88	YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC. <i>Neoplasia</i> , 2017, 19, 1012-1021.	5.3	77
89	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3491-3498.	3.6	33
90	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. <i>Journal of Pathology</i> , 2017, 241, 488-500.	4.5	179

#	ARTICLE	IF	CITATIONS
91	Limited additive value of the Ki67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids. <i>Histopathology</i> , 2017, 70, 412-422.	2.9	41
92	Cytology of Primary Salivary Gland-Type Tumors of the Lower Respiratory Tract: Report of 15 Cases and Review of the Literature. <i>Frontiers in Medicine</i> , 2017, 4, 43.	2.6	12
93	Lung neuroendocrine tumors: pathological characteristics. <i>Journal of Thoracic Disease</i> , 2017, 9, S1442-S1447.	1.4	29
94	Adrenal gland tumors in dairy cattle from Northern Italy: morphological and phenotypical characterization in comparison with human pathology. <i>Polish Journal of Veterinary Sciences</i> , 2017, 20, 779-788.	0.2	1
95	An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 569-576.	3.7	75
96	Cytological features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features and their correlation with tumor histology. <i>Human Pathology</i> , 2016, 54, 134-142.	2.0	190
97	BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2006-2017.	1.1	83
98	Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis. <i>Human Pathology</i> , 2016, 58, 113-122.	2.0	25
99	Androgen deprivation modulates gene expression profile along prostate cancer progression. <i>Human Pathology</i> , 2016, 56, 81-88.	2.0	20
100	The story of poorly differentiated thyroid carcinoma: From Langhans™ description to the Turin proposal via Juan Rosai. <i>Seminars in Diagnostic Pathology</i> , 2016, 33, 277-283.	1.5	21
101	Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2016, 11, 504-515.	1.1	19
102	The AGMA1 poly(amidoamine) inhibits the infectivity of herpes simplex virus in cell lines, in human cervicovaginal histocultures, and in vaginally infected mice. <i>Biomaterials</i> , 2016, 85, 40-53.	11.4	30
103	Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer. <i>Oncotarget</i> , 2016, 7, 14394-14404.	1.8	23
104	Dissecting morphological and molecular heterogeneity in adrenocortical carcinoma. <i>Turk Patoloji Dergisi</i> , 2015, 31 Suppl 1, 98-104.	0.3	6
105	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). <i>Modern Pathology</i> , 2015, 28, 807-821.	5.5	176
106	Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: a case report and review of the literature. <i>BMC Cancer</i> , 2015, 15, 914.	2.6	5
107	Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein. <i>Cancer Letters</i> , 2015, 360, 219-226.	7.2	49
108	Identification of MicroRNAs Differentially Expressed in Lung Carcinoid Subtypes and Progression. <i>Neuroendocrinology</i> , 2015, 101, 246-255.	2.5	45

#	ARTICLE	IF	CITATIONS
109	Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study. <i>Journal of Thoracic Oncology</i> , 2015, 10, 492-499.	1.1	142
110	Classification of lung neuroendocrine tumors: lights and shadows. <i>Endocrine</i> , 2015, 50, 315-319.	2.3	40
111	Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases. <i>Human Pathology</i> , 2015, 46, 1799-1807.	2.0	44
112	Expression Analysis of Genes Involved in DNA Repair or Synthesis in Mixed Neuroendocrine/Nonneuroendocrine Carcinomas. <i>Neuroendocrinology</i> , 2015, 101, 151-160.	2.5	25
113	Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. <i>Annals of Oncology</i> , 2015, 26, 2119-2125.	1.2	196
114	RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. <i>Molecular and Cellular Endocrinology</i> , 2015, 401, 105-110.	3.2	23
115	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. <i>PLoS ONE</i> , 2014, 9, e105855.	2.5	41
116	CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. <i>Oncotarget</i> , 2014, 5, 6191-6205.	1.8	13
117	Therapeutic Biomarkers in Lung Neuroendocrine Neoplasia. <i>Endocrine Pathology</i> , 2014, 25, 371-377.	9.0	12
118	Impact of pregnancy on prognosis of differentiated thyroid cancer: clinical and molecular features. <i>European Journal of Endocrinology</i> , 2014, 170, 659-666.	3.7	67
119	Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma. <i>Modern Pathology</i> , 2014, 27, 1246-1254.	5.5	67
120	RFamide Peptides 43RFa and 26RFa Both Promote Survival of Pancreatic β -Cells and Human Pancreatic Islets but Exert Opposite Effects on Insulin Secretion. <i>Diabetes</i> , 2014, 63, 2380-2393.	0.6	44
121	H-RAS Mutations Are Restricted to Sporadic Pheochromocytomas Lacking Specific Clinical or Pathological Features: Data From a Multi-Institutional Series. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1376-E1380.	3.6	42
122	Mixed Adenoneuroendocrine Carcinomas of the Gastrointestinal Tract: Targeted Next-Generation Sequencing Suggests a Monoclonal Origin of the Two Components. <i>Neuroendocrinology</i> , 2014, 100, 310-316.	2.5	115
123	Interobserver Variability for the WHO Classification of Pulmonary Carcinoids. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1429-1436.	3.7	76
124	Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 1-7.	3.2	25
125	Pathology of the Adrenal Cortex: a Reappraisal of the Past 25 Years Focusing on Adrenal Cortical Tumors. <i>Endocrine Pathology</i> , 2014, 25, 35-48.	9.0	28
126	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. <i>European Urology</i> , 2014, 65, 832-838.	1.9	121

#	ARTICLE	IF	CITATIONS
127	Cell size as a prognostic factor in oncocytic poorly differentiated carcinomas of the thyroid. Human Pathology, 2014, 45, 1489-1495.	2.0	11
128	<i>MEN1</i> Gene Mutation and Reduced Expression Are Associated With Poor Prognosis in Pulmonary Carcinoids. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E374-E378.	3.6	62
129	Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocrine-Related Cancer, 2014, 21, 1-16.	3.1	192
130	Highly Sulfated K5 Escherichia coli Polysaccharide Derivatives Inhibit Respiratory Syncytial Virus Infectivity in Cell Lines and Human Tracheal-Bronchial Histocultures. Antimicrobial Agents and Chemotherapy, 2014, 58, 4782-4794.	3.2	35
131	Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. Human Pathology, 2014, 45, 665-673.	2.0	27
132	MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations. Human Pathology, 2014, 45, 1555-1562.	2.0	50
133	Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing. BMC Cancer, 2013, 13, 114.	2.6	11
134	Characterization of Neuroendocrine Tumors of the Pancreas by Real-Time Quantitative Polymerase Chain Reaction. A Methodological Approach. Endocrine Pathology, 2013, 24, 83-91.	9.0	12
135	An exploration of pathways involved in lung carcinoid progression using gene expression profiling. Carcinogenesis, 2013, 34, 2726-2737.	2.8	49
136	Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Human Pathology, 2013, 44, 822-828.	2.0	76
137	Achaete-scute homolog 1 as a marker of poorly differentiated neuroendocrine carcinomas of different sites: a validation study using immunohistochemistry and quantitative real-time polymerase chain reaction on 335 cases. Human Pathology, 2013, 44, 1391-1399.	2.0	39
138	The Reticulin Algorithm for Adrenocortical Tumor Diagnosis. American Journal of Surgical Pathology, 2013, 37, 1433-1440.	3.7	75
139	Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. European Journal of Endocrinology, 2013, 169, 263-270.	3.7	118
140	CD44 and OTP Are Strong Prognostic Markers for Pulmonary Carcinoids. Clinical Cancer Research, 2013, 19, 2197-2207.	7.0	77
141	Human ASH-1 Promotes Neuroendocrine Differentiation in Androgen Deprivation Conditions and Interferes With Androgen Responsiveness in Prostate Cancer Cells. Prostate, 2013, 73, 1241-1249.	2.3	26
142	Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenetics and Genomics, 2013, 23, 293-300.	1.5	37
143	Tumor Staging But Not Grading Is Associated With Adverse Clinical Outcome in Neuroendocrine Tumors of the Appendix. American Journal of Surgical Pathology, 2013, 37, 606-612.	3.7	58
144	Ribonucleotide Reductase Large Subunit (<i>RRM1</i>) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. Clinical Cancer Research, 2012, 18, 3452-3461.	7.0	64

#	ARTICLE	IF	CITATIONS
145	Inhibition of Human Respiratory Syncytial Virus Infectivity by a Dendrimeric Heparan Sulfate-Binding Peptide. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5278-5288.	3.2	47
146	Oncocytic Adrenocortical Tumors. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1882-1893.	3.7	52
147	The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 393-402.	2.8	27
148	Hyalinizing Trabecular Tumor of the Thyroid: A Case Report. <i>Head and Neck Pathology</i> , 2011, 5, 423-427.	2.6	11
149	The Weiss Score and Beyond—Histopathology for Adrenocortical Carcinoma. <i>Hormones and Cancer</i> , 2011, 2, 333-340.	4.9	91
150	Mammalian Target of Rapamycin Pathway Activation Is Associated to RET Mutation Status in Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2146-2153.	3.6	44
151	Adrenocortical Tumors With Myxoid Features: A Distinct Morphologic and Phenotypic Variant Exhibiting Malignant Behavior. <i>American Journal of Surgical Pathology</i> , 2010, 34, 973-983.	3.7	81
152	Increased neuroendocrine cells in resected metastases compared to primary colorectal adenocarcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 457, 521-527.	2.8	16
153	Poorly Differentiated Thyroid Carcinoma: 5 Years after the 2004 WHO Classification of Endocrine Tumours. <i>Endocrine Pathology</i> , 2010, 21, 1-6.	9.0	56
154	The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy. <i>Prostate</i> , 2010, 70, 718-726.	2.3	49
155	Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. <i>Endocrine-Related Cancer</i> , 2010, 17, 977-987.	3.1	84
156	Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 clinically aggressive cases. <i>Annals of Oncology</i> , 2010, 21, 548-555.	1.2	144
157	Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. <i>Endocrine-Related Cancer</i> , 2010, 17, 445-453.	3.1	138
158	Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. <i>Modern Pathology</i> , 2010, 23, 1269-1278.	5.5	145
159	Ca ²⁺ is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. <i>Journal of Pathology</i> , 2009, 218, 66-75.	4.5	33
160	Obestatin in human neuroendocrine tissues and tumours: expression and effect on tumour growth. <i>Journal of Pathology</i> , 2009, 218, 458-466.	4.5	42
161	Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. <i>Histopathology</i> , 2009, 55, 535-543.	2.9	110
162	RAS Mutations Are the Predominant Molecular Alteration in Poorly Differentiated Thyroid Carcinomas and Bear Prognostic Impact. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4735-4741.	3.6	181

#	ARTICLE	IF	CITATIONS
163	Poorly Differentiated Carcinoma of the Thyroid Gland. , 2009, 14, 219-223.		4
164	A Practical Diagnostic Approach to Solid/Trabecular Nodules in the Thyroid. Endocrine Pathology, 2008, 19, 75-81.	9.0	20
165	Diagnostic Controversies in Vascular Proliferations of the Thyroid Gland. Endocrine Pathology, 2008, 19, 175-183.	9.0	30
166	Poorly Differentiated Thyroid Carcinoma: Diagnostic Features and Controversial Issues. Endocrine Pathology, 2008, 19, 150-155.	9.0	62
167	Human ASH1 expression in prostate cancer with neuroendocrine differentiation. Modern Pathology, 2008, 21, 700-707.	5.5	51
168	Somatostatin, cortistatin and their receptors in tumours. Molecular and Cellular Endocrinology, 2008, 286, 219-229.	3.2	61
169	Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors. Clinical Cancer Research, 2008, 14, 1059-1064.	7.0	81
170	Pathological and molecular features of adrenocortical carcinoma: an update. Journal of Clinical Pathology, 2008, 61, 787-793.	2.0	61
171	Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocrine-Related Cancer, 2008, 15, 1043-1053.	3.1	141
172	Excision Repair Cross Complementing-1 and Topoisomerase III β Gene Expression in Small-Cell Lung Cancer Patients Treated with Platinum and Etoposide: A Retrospective Study. Journal of Thoracic Oncology, 2008, 3, 583-589.	1.1	41
173	Poorly Differentiated Thyroid Carcinoma: The Turin Proposal for the Use of Uniform Diagnostic Criteria and an Algorithmic Diagnostic Approach. American Journal of Surgical Pathology, 2007, 31, 1256-1264.	3.7	521
174	Cell Membrane Reactivity of MIB-1 Antibody to Ki67 in Human Tumors: Fact or Artifact?. Applied Immunohistochemistry and Molecular Morphology, 2007, 15, 220-223.	1.2	74
175	Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Modern Pathology, 2007, 20, 1172-1182.	5.5	266
176	Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 51-59.	2.8	43
177	Goblet cell carcinoids and other mixed neuroendocrine/nonneuroendocrine neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 61-69.	2.8	25
178	ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Annals of Oncology, 2006, 17, 1818-1825.	1.2	301
179	Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas. Modern Pathology, 2006, 19, 1563-1569.	5.5	47
180	Clinico-pathological features of a series of 11 oncocytic endocrine tumours of the pancreas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 545-551.	2.8	41

#	ARTICLE	IF	CITATIONS
181	The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine–endocrine neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 499-506.	2.8	97
182	Galectin-3 and Ki-67 Expression in Multiglandular Parathyroid Lesions. American Journal of Clinical Pathology, 2006, 126, 59-66.	0.7	27
183	Immunohistochemical study of neuroendocrine differentiation in primary glandular lesions and tumors of the urinary bladder. , 2005, 27, 218-24.		6
184	Somatostatin Receptors and Their Interest in Diagnostic Pathology. Endocrine Pathology, 2004, 15, 275-292.	9.0	43
185	Prognostic Factors of Clinical Interest in Poorly Differentiated Carcinomas of the Thyroid. Endocrine Pathology, 2004, 15, 313-318.	9.0	29
186	Galectin-3 and HBME-1 expression in oncocyctic cell tumors of the thyroid. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 183-8.	2.8	48
187	Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns. Cancer, 2004, 100, 950-957.	4.1	198
188	Ghrelin in Fetal Thyroid and Follicular Tumors and Cell Lines. American Journal of Pathology, 2003, 162, 645-654.	3.8	118
189	Heterogeneous versus homogeneous genetic nature of multiple foci of in situ carcinoma of the breast. Human Pathology, 2003, 34, 1163-1169.	2.0	10
190	Merkel Cell Carcinomas: Expression of S-Phase Kinase-Associated Protein 2 (Skp2), p27, and Proliferation Markers. Endocrine Pathology, 2003, 14, 221-230.	9.0	2
191	Glutathione S-transferase T1 and M1 polymorphisms and risk of thyroid neoplasms. Archive of Oncology, 2003, 11, 185-185.	0.2	0
192	Expression of Ghrelin and of the GH Secretagogue Receptor by Pancreatic Islet Cells and Related Endocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1300-1308.	3.6	306
193	E2F-1 Transcription Factor Is Overexpressed in Oxyphilic Thyroid Tumors. Modern Pathology, 2002, 15, 1038-1043.	5.5	20
194	RET Activation and Clinicopathologic Features in Poorly Differentiated Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 370-379.	3.6	99
195	Ghrelin Expression in Fetal, Infant, and Adult Human Lung. Journal of Histochemistry and Cytochemistry, 2002, 50, 1013-1021.	2.5	123
196	Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 440, 461-475.	2.8	287
197	Expression of Ghrelin and of the GH Secretagogue Receptor by Pancreatic Islet Cells and Related Endocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1300-1308.	3.6	125
198	Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clinical Endocrinology, 2001, 54, 641-649.	2.4	122

#	ARTICLE	IF	CITATIONS
199	Classic and Recent Special Stains Used in Differential Diagnosis of Endocrine Tumors. <i>Endocrine Pathology</i> , 2001, 12, 379-388.	9.0	7
200	Extensive DNA Fragmentation in Oxyphilic Cell Lesions of the Thyroid. <i>Journal of Histochemistry and Cytochemistry</i> , 2001, 49, 1003-1011.	2.5	15
201	RET/PTC Activation in Hyalinizing Trabecular Tumors of the Thyroid. <i>American Journal of Surgical Pathology</i> , 2000, 24, 1615-1621.	3.7	152
202	Thyroglobulin mRNA expression helps to distinguish anaplastic carcinoma from angiosarcoma of the thyroid. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000, 437, 635-642.	2.8	34
203	Post-incubation Heating Significantly Improves Tyramide Signal Amplification. <i>Journal of Histochemistry and Cytochemistry</i> , 2000, 48, 1583-1585.	2.5	14
204	Thyroid carcinomas with mixed follicular and C-cell differentiation patterns. <i>Seminars in Diagnostic Pathology</i> , 2000, 17, 109-19.	1.5	35
205	Mixed Medullary-Follicular Thyroid Carcinoma. <i>American Journal of Pathology</i> , 1999, 155, 1499-1509.	3.8	108